

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Souza Marcio</u> (Last) (First) (Middle) <u>C/O PTC THERAPEUTICS, INC.</u> <u>100 CORPORATE COURT</u> (Street) <u>SOUTH</u> <u>NJ</u> <u>07080</u> <u>PLAINFIELD</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>05/31/2017</u>	3. Issuer Name and Ticker or Trading Symbol <u>PTC THERAPEUTICS, INC.</u> [<u>PTCT</u>] 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <u>X</u> Officer (give title below) Other (specify below) <u>Chief Operating Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <u>X</u> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	---	--	--

Table I - Non-Derivative Securities Beneficially Owned			
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>36,457</u> ⁽¹⁾	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Option (Right To Buy)</u>	<u>(2)</u>	<u>07/31/2024</u>	<u>Common Stock</u>	<u>30,000</u>	<u>26.42</u>	<u>D</u>	
<u>Stock Option (Right To Buy)</u>	<u>(3)</u>	<u>01/02/2025</u>	<u>Common Stock</u>	<u>10,525</u>	<u>51</u>	<u>D</u>	
<u>Stock Option (Right To Buy)</u>	<u>(4)</u>	<u>01/03/2026</u>	<u>Common Stock</u>	<u>16,000</u>	<u>30.86</u>	<u>D</u>	
<u>Stock Option (Right To Buy)</u>	<u>(5)</u>	<u>11/16/2026</u>	<u>Common Stock</u>	<u>2,000</u>	<u>12.64</u>	<u>D</u>	
<u>Stock Option (Right To Buy)</u>	<u>(6)</u>	<u>01/02/2027</u>	<u>Common Stock</u>	<u>23,100</u>	<u>11.23</u>	<u>D</u>	
<u>Stock Option (Right To Buy)</u>	<u>(7)</u>	<u>05/17/2027</u>	<u>Common Stock</u>	<u>10,000</u>	<u>12.92</u>	<u>I</u>	<u>By Spouse</u>

Explanation of Responses:

1. Includes 4,000 shares of a Restricted stock award awarded to the Reporting Person, which vests in four equal annual installments over four years, commencing on January 3, 2018.

2. This option was granted on July 31, 2014 and vests over four years, with 25% of the shares underlying the option vested on July 31, 2015, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on October 31, 2015.

3. This option was granted on January 2, 2015 and vests over four years, with 25% of the shares underlying the option vested on January 2, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2016.

4. This option was granted on January 4, 2016 and vests over four years, with 25% of the shares underlying the option vested on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.

5. This option was granted on November 17, 2016 and vests over four years, with 25% of the shares underlying the option vesting on November 17, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on February 17, 2018.

6. This option was granted on January 3, 2017 and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.

7. This option was granted on May 17, 2017 and vests over four years, with 25% of the shares underlying the option vesting on May 8, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on August 8, 2018.

Remarks:

Avraham S. Adler, attorney-in-fact 06/02/2017
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Donald Mankoff, Mark Boulding, Colleen Diver Johnson, Avraham Adler & (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of PTC Therapeutics, Inc. (the "Company"), Forms 3, 4, (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or (3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any third (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in fact, may be of benefit to, in the best interest of the Company. The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, and proper or allowable to be done in connection with the foregoing, and This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's securities. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 19th day of May, 2017.

/s/ Marcio Souza
Signature

Marcio Souza
Print Name